Curasight A/S (NGM:CURAS)

Market Cap	705.32M
Revenue (ttm)	n/a
Net Income (ttm)	-71.43M
Shares Out	45.87M
EPS (ttm)	-1.78
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	37,027
Average Volume	127,706
Open	10.55
Previous Close	10.35
Day's Range	10.10 - 10.55
52-Week Range	1.80 - 11.80
Beta	0.01
RSI	71.66
Earnings Date	Nov 27, 2025

About Curasight

Curasight A/S develops therapeutic and diagnostic solutions for the treatment of cancer. It develops uTREAT therapeutic solutions, that are in Phase IIb clinical trials to treat glioblastoma, non-small cell lung cancers, neuroendocrine neoplasms, head and neck cancer, and pancreatic cancers. The company is also developing uTRACE diagnostic solutions, which have completed Phase II clinical trial for the treatment of glioblastoma, prostate cancer, neuroendocrine neoplasms, head and neck cancer, breast cancer, and urinary bladder cancer; and is in...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2013
• Employees: 4
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: CURAS

Financial Performance

Financial numbers in DKK